Find Remogliflozin Etabonate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 442201-24-3, Gsk-189075, Gsk-189075a, Gsk189075a, Remogliflozin etabonate [inn], Tr0qt6qsul
Molecular Formula
C26H38N2O9
Molecular Weight
522.6  g/mol
InChI Key
UAOCLDQAQNNEAX-ABMICEGHSA-N
FDA UNII
TR0QT6QSUL

Remogliflozin Etabonate
Remogliflozin Etabonate is an orally available prodrug of remogliflozin, a benzylpyrazole glucoside-based inhibitor of renal sodium-glucose co-transporter subtype 2 (SGLT2) with antihyperglycemic activity. Upon administration and absorption, the inactive prodrug is converted to its active form remogliflozin and acts selectively on the sodium-glucose co-transporter subtype 2 (SGLT2).
1 2D Structure

Remogliflozin Etabonate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate
2.1.2 InChI
InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
2.1.3 InChI Key
UAOCLDQAQNNEAX-ABMICEGHSA-N
2.1.4 Canonical SMILES
CCOC(=O)OCC1C(C(C(C(O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O
2.1.5 Isomeric SMILES
CCOC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O
2.2 Other Identifiers
2.2.1 UNII
TR0QT6QSUL
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1h-pyrazol-3-yl 6-o-(ethoxycarbonyl)-beta-d-glucopyranoside

2.3.2 Depositor-Supplied Synonyms

1. 442201-24-3

2. Gsk-189075

3. Gsk-189075a

4. Gsk189075a

5. Remogliflozin Etabonate [inn]

6. Tr0qt6qsul

7. Ethyl (((2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1h-pyrazol-3-yl)oxy)tetrahydro-2h-pyran-2-yl)methyl) Carbonate

8. Ethyl [(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl Carbonate

9. 5-methyl-4-(4-(1-methylethoxy)benzyl)-1-(1-methylethyl)-1h-pyrazol-3-yl 6-o-(ethoxycarbonyl)-beta-d-glucopyranoside

10. Unii-tr0qt6qsul

11. Kgt-1681

12. Remogliflozin Etabonate [usan]

13. Beta-d-glucopyranoside, 5-methyl-4-((4-(1-methylethoxy)phenyl)methyl)-1-(1-methylethyl)-1h-pyrazol-3-yl, 6-(ethyl Carbonate)

14. Beta-d-glucopyranoside, 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1h-pyrazol-3-yl, 6-(ethyl Carbonate)

15. S0993

16. Schembl721678

17. Chembl2028665

18. Dtxsid50963191

19. Chebi:177541

20. Gsk 189075a

21. Zinc3979756

22. Remogliflozin Etabonate (usan/inn)

23. Bdbm50559516

24. Gsk189075

25. Bhv-091009

26. Db12935

27. Remogliflozin Etabonate (gsk189075)

28. Remogliflozin Etabonate [who-dd]

29. Br162756

30. Hy-14945

31. Cs-0003650

32. D10055

33. Q7312052

34. 3-(6-o-ethoxycarbonyl-beta-d-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)-methyl]-1-isopropyl-5-methylpyrazole

35. 3-(6-o-ethoxycarbonyl-beta-d-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-1-isopropyl-5-methylpyrazole

36. 4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1h-pyrazole-3-yl 6-o-(ethoxycarbonyl)-beta-d-glucopyranoside

37. 5-methyl-1-(propan-2-yl)-4-((4-((propan-2-yl)oxy)phenyl)methyl)-1h-pyrazol-3-yl 6-o-(ethoxycarbonyl)-.beta.-d-glucopyranoside

38. 5-methyl-4-(4-(1-methylethoxy)benzyl)-1-(1-methylethyl)-1h-pyrazol-3-yl 6-o- (ethoxycarbonyl)-.beta.-d-glucopyranoside

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 522.6 g/mol
Molecular Formula C26H38N2O9
XLogP33
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count10
Rotatable Bond Count12
Exact Mass522.25773079 g/mol
Monoisotopic Mass522.25773079 g/mol
Topological Polar Surface Area142 Ų
Heavy Atom Count37
Formal Charge0
Complexity704
Isotope Atom Count0
Defined Atom Stereocenter Count5
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Sodium-Glucose Transporter 2 Inhibitors

Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)


Listed Suppliers

read-more
read-more

01

Hetero Drugs

India
Medlab Asia & Asia Health
Not Confirmed
arrow

Hetero Drugs

India
arrow
Medlab Asia & Asia Health
Not Confirmed

Remogliflozin Etabonate

About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
blank

02

Medlab Asia & Asia Health
Not Confirmed
arrow
arrow
Medlab Asia & Asia Health
Not Confirmed

Remogliflozin Etabonate

About the Company : Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Cente...

Founded in 2010, Ausun Pharmaceutical is a public company, specialized in high-tech. threshold Generic API Dev. & providing CDMO services. Ausun owns & operates 1 on-site R&D Center & 1 Mfg. Site which has been certified by US FDA, JPMDA & EMA, supported by >550 highly trained professionals across departments & >200 scientists to bring high quality products to customers. More than 130 products/projects have been successfully developed since founded. Process Innovation, R&D Efficiency & Cost Effectiveness are Ausun's key competencies. Create Chemistry and to be the 1st Class Worldwide Pharmaceutical Corporation is our goal.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty